For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 24,365 | 27,417* | 31,450 | 38,278 |
| General and administrative | 20,975 | 11,372* | 9,681 | 8,468 |
| Total operating expenses | 45,340 | 38,788 | 41,131 | 46,746 |
| Loss from operations | -45,340 | -38,788* | -41,131 | -46,746 |
| Interest income, net | 5,996 | 4,450* | 4,195 | 3,474 |
| Other income (expense) | 5 | -3* | 4 | -2 |
| Total other income, net | 6,001 | 4,447* | 4,199 | 3,472 |
| Net loss | -39,339 | -34,342 | -36,932 | -43,274 |
| Basic EPS | -0.47 | -0.513 | -0.52 | -0.66 |
| Diluted EPS | -0.47 | -0.513 | -0.52 | -0.66 |
| Basic Average Shares | 82,834,752 | 66,923,264 | 70,594,504 | 65,451,297 |
| Diluted Average Shares | 82,834,752 | 66,923,264 | 70,594,504 | 65,451,297 |
Mineralys Therapeutics, Inc. (MLYS)
Mineralys Therapeutics, Inc. (MLYS)